Fate Therapeutics
Fate Therapeutics
FATE
NASDAQ
3.67
USD
138.31%
About
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders. Its proprietary induced pluripotent stem cells (iPSC) product platform combines multiplexed-engineering of human iPSCs with single-cell selection to create clonal master iPSC lines.
The Company’s platform is designed to overcome numerous limitations associated with the manufacture of cell therapies using patient- or donor-sourced cells. Utilizing its proprietary iPSC product platform, it is advancing off-the-shelf, multiplexed-engineered natural killer (NK) cell and T-cell product candidates which are selectively designed, incorporate novel synthetic controls of cell function.
Its pipeline of iPSC-derived, chimeric antigen receptor (CAR)-targeted NK cell and T-cell product candidates include FT819, FT522, FT576, FT825, FT819, FT522, and others..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 1.4M |
| Three Month Average Volume | 41.9M |
| High Low | |
| Fifty-Two Week High | 8.83 USD |
| Fifty-Two Week Low | 1.63 USD |
| Fifty-Two Week High Date | 07 Mar 2024 |
| Fifty-Two Week Low Date | 30 Oct 2023 |
| Price and Volume | |
| Current Price | 3.67 USD |
| Beta | 2 |
| Relative Price Change | |
| Four Week Relative Price Change | -24.97% |
| Thirteen Week Relative Price Change | -6.82% |
| Twenty-Six Week Relative Price Change | -56.88% |
| Fifty-Two Week Relative Price Change | 16.69% |
| Year-to-Date Relative Price Change | -17.13% |
| Price Change | |
| One Day Price Change | 3.67% |
| Thirteen Week Price Change | -0.27% |
| Twenty-Six Week Price Change | -52.58% |
| Five Day Price Change | -4.43% |
| Fifty-Two Week Price Change | 46.22% |
| Year-to-Date Price Change | -1.87% |
| Month-to-Date Price Change | -31.14% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 3.73545 USD |
| Book Value Per Share (Most Recent Quarter) | 3.4869 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 3.73545 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 3.4869 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -1.69655 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0.64559 USD |
| Revenue Per Share (Trailing Twelve Months) | 0.1185 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -1.63526 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -1.7076 USD |
| Normalized (Last Fiscal Year) | -1.63526 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -1.63526 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -1.7076 USD |
| Including Extraordinary Items (Last Fiscal Year) | -1.63526 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -1.7076 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 3.19562 USD |
| Cash Per Share (Most Recent Quarter) | 2.67791 USD |
| Cash Flow Per Share (Last Fiscal Year) | -1.44931 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -1.50623 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -1.36088 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -299 |
| Cash Flow Revenue (Trailing Twelve Months) | -1,148 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -1,426.67% |
| Pretax Margin (Last Fiscal Year) | -253.30% |
| Pretax Margin (5 Year) | -359.33% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -299.86% |
| Operating Margin (Trailing Twelve Months) | -1,587.28% |
| Operating Margin (5 Year) | -366.46% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -253.30% |
| Net Profit Margin (Trailing Twelve Months) | -1,426.67% |
| Net Profit Margin (5 Year) | -359.33% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | 8.53% |
| Tangible Book Value (5 Year) | 18.08% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | 625.83% |
| Revenue Growth (3 Year) | 68.05% |
| Revenue Change (Trailing Twelve Months) | -89.67% |
| Revenue Per Share Growth | 50.24% |
| Revenue Growth (5 Year) | 26.43% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | 21.72% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 38.98% |
| EPS Change (Trailing Twelve Months) | 21.30% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 1 |
| Price to Tangible Book (Most Recent Quarter) | 1 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -304,879,000 |
| Net Debt (Last Fiscal Year) | -315,175,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 7 |
| Price to Sales (Trailing Twelve Months) | 34 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 1 |
| Price to Book (Most Recent Quarter) | 1 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 8 |
| Current Ratio (Most Recent Quarter) | 9 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -138,416,000 |
| Free Cash Flow (Trailing Twelve Months) | -141,449,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -26.56% |
| Return on Assets (Trailing Twelve Months) | -31.56% |
| Return on Assets (5 Year) | -31.82% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -37.76% |
| Return on Equity (Trailing Twelve Months) | -42.10% |
| Return on Equity (5 Year) | -45.05% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -30.40% |
| Return on Investment (Trailing Twelve Months) | -33.99% |
| Return on Investment (5 Year) | -36.05% |